Enabling Technologies for Tissue Engineering and Regenerative Medicine (R01)

The summary for the Enabling Technologies for Tissue Engineering and Regenerative Medicine (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Enabling Technologies for Tissue Engineering and Regenerative Medicine (R01): The National Institutes of Health (National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), and National Institute of Dental and Craniofacial Research (NIDCR)), the National Institute of Standards and Technology (Chemical Science and Technology Laboratory (CSTL) and Materials Science and Engineering Laboratory (MSEL)), and the National Science Foundation (Division of Bioengineering and Environmental Systems (BES)), issue this Funding Opportunity Announcement (FOA) to solicit design or hypothesis - driven research applications to promote the development of innovative technologies, tools, methods, and devices that will enable tissue engineering and regenerative medicine. The overall goal is to engineer functional tissues in vitro for implantation in vivo or to foster tissue regeneration directly in vivo, with the purpose of replacing, repairing, preserving, or enhancing organ function lost due to disease, injury, or aging, or for use as 3D tissue model system for drug development. The intent of this FOA is to encourage applications whose primary focus is on developing enabling technologies for tissue engineering and regenerative medicine, with the ultimate goal of improving human quality of life. This may include reproductive as well as somatic tissues. While full validation of new technologies may depend upon demonstration of effectiveness toward a specific medical challenge, the NIBIB and NSF preference will be given to approaches with general utility across a wide spectrum of applications. The NHLBI, NIAMS, NICHD, NIDCD, NIDCR, and NIST interests are given under the Research Objectives. All applications must focus on the development of the enabling technologies. The funding agencies particularly encourage investigators from the engineering, physical, and computational sciences to collaborate with those of life sciences or vice versa to submit an application to this FOA. Specific scientific interests for this FOA fall in the following research areas: